Evaluation of serum Level of Human Beta Defensin 1 patients With Alopecia Areata | ||||
| Benha Journal of Applied Sciences | ||||
| Article 4, Volume 7, Issue 10, October 2022, Page 25-32 PDF (606.12 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2022.284644 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| A.A. Abd El-moneam; A.A. Ebrahim; A.I. Mustafa; W.A. Abd-Halim | ||||
| Dermatology Venereology and Andrology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
| Abstract | ||||
| Alopecia areata is an autoimmune disease characterized by non-scarring hair loss in single or multiple areas of the scalp, face or body. Human beta-defensin 1 is a protein that in humans is encoded by the DEFB1 gene. Defensins form a family of microbicidal and cytotoxic peptides made by neutrophils. Human beta defensin 1 was purified from hemodialysate fluid, but its tissue sources were not identified. Aim:To evaluate serum level of human beta defensin 1 to reveal its role in alopecia areata pathogenesis and to relate with studied clinical parameters. Patients and methods: This prospective casecontrol study was included fourty patients with AA (Group A) and fourty age and sex matched apparently healthy subjects as a control group (Group B). Patients were selected from the Dermatology outpatient clinic of Benha University Hospitals in the period between December 2018 and June 2019. Results:we found that AA group showed no significant difference in serum level of HBD-1 when compared to control group (p=0.03). HBD-1 concentration was not considered as predictor of AA.Conclusion: HBD-1 concentration was not considered as a predictor of AA susceptibility and severity. | ||||
| Keywords | ||||
| Hair pull test; Dermoscope | ||||
|
Statistics Article View: 122 PDF Download: 238 |
||||
